Gary Giarratano joins Radient Pharmaceuticals
Takes position of director of North American sales and marketing
Armed with a successful track record in the IVD industry, Giarratano brings more than 20 years of healthcare, sales and marketing leadership experience to the California-based firm. He is recognised for his contributions in new market development for Carcinoembryonic Antigen (CEA), PSA and HPV and led sales for the first company to secure US FDA approval on each of these assays.
‘Gary thoroughly understands the intricacies of the IVD marketplace and has repeatedly successfully driven market share for various new test kit products. We expect him to do the same for Onko-Sure,’ said Douglas MacLellan, ceo of RPC.
You may also like
Regulatory
Grifols gets nod from European Medicines Agency for entire value chain of Grifols Egypt
The institution's certification endorses the entire plasma value chain under the highest European standards and opens the door for Egypt to, once domestic needs are met, export to other markets including Europe
Regulatory
Regulating innovation: a new focus on digital mental health technologies (DMHTs)
IMed Consultancy’s Benjamin Austin provides a clear understanding of how digital mental health technologies are innovating care and describes the evolving regulatory frameworks that ensure their safety and effectiveness
Regulatory
ten23 health QC lab to support commercial product testing for US customer following FDA approvals
This pivotal regulatory milestone enables FDA-compliant release and stability testing for injectable drug products throughout the clinical and commercial phases, in addition to manufacturing the commercial product